Drawing for PROSTATESENTRY

USPTO serial 85762609

PROSTATESENTRY

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
DESAI, BRIN ANDERSON
Law office
TMO LAW OFFICE 111 - SENIOR ATTORNEY

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with PROSTATESENTRY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew S. Ehard

ANDREW S. EHARD MERCHANT & GOULD P.C.PO BOX 2910MINNEAPOLIS, MN 55402-0910UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
010blood drawing apparatus; diagnostic kits; diagnostic kits comprising molecular biological reagents useful for detecting gene expression products, including ribonucleic acid (RNA) or proteins, as an indication of body state, including body health, condition, disease , response to external stimuli, or response to therapeutic treatment; diagnostic services, including diagnosing, preventing and predicting disease, identifying risk factors of disease, prognostic testing, gene and protein testing, identifying physiological characteristics, and evaluating efficacy of treatment; medical services, including clinical laboratory testing services, and patient triage or risk stratification services, including determination of likelihood or odds of having a particular disease or condition as an aid to optimize further testing or treatment options for patients, medical and diagnostic services, including diagnosing, preventing and predicting disease, identifying disease risk factors, diagnostic testing, gene and protein testing, identifying physiological characteristics, establishing individual preventative care programs, establishing disease treatment based on gene and protein expression and/or activity, and monitoring of patient health progression; medical and diagnostic services, namely evaluating clinical trial progress, and drug monitoring; providing genomic, proteomic and gene expression profiles useful in selecting therapeutics, evaluating treatment progression, and prognosing disease or disease progression; providing genomic, proteomic and gene expression profiles useful in evaluating the efficacy and toxicity of treatments, and identifying disease heredity risk factors; research and development, validation testing, data analysis and product development in the fields of biology, systems biology, biochemistry, molecular biology, genomics, proteomics, diagnostics, toxicogenomics, pharmacogenomics and personalized medicine; computer services, including providing a website for patients and medical professionals featuring educational information about personalized health management, disease, and disease risk assessment services and screening products; computer services, including computer tracking of and providing access to databases of life sciences information via global, national and local computer networks in the field of pharmacogenomics, diagnostics, personalized medicine and toxicogenomics; computer services, including maintaining and providing access to a patient registry containing personalized health management information accessible via global, national and local computer networksACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jan 23, 2017MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 23, 2017MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 23, 2017ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 2, 2016CNSIINQUIRY AS TO SUSPENSION MAILED—
May 2, 2016CNSISUSPENSION INQUIRY WRITTEN—
Apr 5, 2016RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Sep 30, 2015CNSLLETTER OF SUSPENSION MAILED—
Sep 29, 2015CNSLSUSPENSION LETTER WRITTEN—
Sep 8, 2015RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Mar 4, 2015RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 4, 2015RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Feb 25, 2015ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Sep 3, 2014RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 11, 2014DOCKASSIGNED TO EXAMINER—
Mar 3, 2014RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 26, 2013RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Feb 25, 2013CNSLLETTER OF SUSPENSION MAILED—
Feb 25, 2013CNSLSUSPENSION LETTER WRITTEN—
Feb 14, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 14, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 11, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 23, 2012CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 21, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 16, 2012DOCKASSIGNED TO EXAMINER—
Nov 16, 2012ALIEASSIGNED TO LIE—
Nov 6, 2012PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Oct 31, 2012MPMKNOTICE OF PSEUDO MARK MAILED—
Oct 30, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 27, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance